Claims for Patent: 8,436,010

Summary for Patent: 8,436,010

Title:	Treatment of solid tumors with rapamycin derivatives
Abstract:	Rapamycin derivatives have interesting effects in the treatment of solid tumors, optionally in combination with a chemotherapeutic agent.
Inventor(s):	Lane; Heidi (Basel, CH), O'Reilly; Terence (Basel, CH), Wood; Jeanette Marjorie (Biel-Benken, CH)
Assignee:	Novartis Pharmaceuticals Corporation (East Hanover, NJ)
Application Number:	13/403,578
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,436,010
Patent Claims:	1. A method for inhibiting growth of solid tumors of the breast in a subject having a solid breast tumor, said method consisting of administering to said subject a therapeutically effective amount of a compound of formula I concomitantly or sequentially with exemestane, ##STR00002## wherein R.sub.1 is CH.sub.3, R.sub.2 is --CH.sub.2--CH.sub.2--OH, and X is .dbd.O. 2. The method of claim 1 wherein the solid tumor of the breast has metastasized. 3. The method of claim 1 wherein the compound of formula I and the exemestane are administered orally. 4. The method of claim 1 wherein the compound of formula I is administered at a daily dose range of from about 0.1 to 25 mg, as a single dose or in divided doses. 5. The method of claim 1 wherein the compound of formula I is administered in a unit dosage form of from about 0.05 to 12.5 mg. 6. The method of claim 5 wherein the compound of formula I is administered in a unit dosage form of from about 0.25 to 10 mg. 7. The method of claim 6 wherein the compound of formula I is administered in a unit dosage form of 10 mg. 8. The method of claim 1 wherein the exemestane is administered orally in a dosage range from about 5 to about 200 mg per day. 9. The method of claim 8 wherein the exemestane is administered orally in a dosage range from about 10 to 25 mg per day. 10. The method of claim 1 wherein the exemestane is admninstered parenterally from about 50 to about 500 mg per day. 11. The method of claim 10 wherein the exemestane is administered parenterally from about 100 to about 250 mg per day.